Johann Leban

USPTO Granted Patents = 17 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 286(Granted Patents)

Location History:

Martinsried, DE (2009)
Germering, DE (2006 - 2010)
Planegg, DE (2012)
Planegg-Martinsried, DE (2013 - 2014)
Vienna, AT (2017 - 2020)

Company Filing History:

Years Active: 2006-2020

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10633369 - Method of inhibiting DYRK1B (2020-04-28),

2. 10221147 - Heterocyclic compounds with working memory enhancing activity (2019-03-05),

3. 10005769 - 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors (2018-06-26),

4. 9951050 - Method of inhibiting DYRK1B (2018-04-24),

5. 9580438 - Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders (2017-02-28),

6. 8653138 - Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents (2014-02-18),

7. 8592456 - IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation (2013-11-26),

8. 8354436 - IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation (2013-01-15),

9. 8354433 - Anti-inflammatory agents as virostatic compounds (2013-01-15),

10. 8106048 - Heterocyclic NF-κB inhibitors (2012-01-31),

11. 7812041 - Heterocyclic NF-κB inhibitors (2010-10-12),

12. 7601745 - Heterocyclic NF-kB inhibitors (2009-10-13),

13. 7531517 - Inhibitors of cancer cell, T-cell and keratinocyte proliferation (2009-05-12),

14. 7365094 - Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents (2008-04-29),

15. 7317030 - Compounds as inhibitors of cell proliferation and viral infections (2008-01-08),

Title: Johann Leban: Innovator in Cancer Treatment and Memory Enhancement

Introduction

Johann Leban is a prominent inventor based in Vienna, Austria. He has made significant contributions to the fields of cancer treatment and cognitive enhancement through his innovative patents. With a total of 17 patents to his name, Leban's work continues to impact the scientific community.

Latest Patents

One of Johann Leban's latest patents is a method of inhibiting DYRK1B. This invention relates to a DYRK1B inhibitor for use in the treatment of cancer, particularly in cases where the hedgehog signaling pathway is activated. Notably, this activation occurs independently of signaling by the G protein-coupled receptor Smoothened. Another significant patent involves heterocyclic compounds with working memory enhancing activity. This disclosure pertains to a chemical compound designed to improve short-term memory and working memory, utilizing a specific thiazole ring structure.

Career Highlights

Throughout his career, Johann Leban has worked with notable companies such as 4SC AG and 4SC Discovery GmbH. His expertise in the field has allowed him to develop groundbreaking solutions that address critical health issues.

Collaborations

Johann Leban has collaborated with esteemed colleagues, including Roland Baumgartner and Stefan Tasler. These partnerships have fostered an environment of innovation and creativity, leading to the development of impactful inventions.

Conclusion

Johann Leban's contributions to the fields of cancer treatment and cognitive enhancement through his patents exemplify his dedication to innovation. His work continues to inspire advancements in medical science and technology.

This text is generated by artificial intelligence and may not be accurate.